ArticleBMC plant biology2026
The engineered Immunoprotein enhance broad-spectrum disease resistance in solanaceous crops.
Article in BMC plant biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The sustainability of global agricultural systems, a cornerstone for both economic security and food supply chains, is increasingly compromised by phytopathogen invasions. Herein, we characterize RP151—a novel biopesticide engineered through rational concatenation of plant immunity-stimulating peptides. This recombinant protein demonstrates exceptional bioavailability in Solanaceous crops like tobacco and tomato, inducing multifaceted defense responses within 24 h post-application, as evidenced by ROS burst, MAPK cascade activation, and localized callose deposition. Mechanistic studies reveal that RP151-mediated resistance against TMV and its co-infection with CMV primarily operates through SA-dependent signaling. In comparative trials, RP151 significantly prolonged SAR duration and effectively suppressed lesion expansion in TMV-challenged plants relative to conventional antiviral agents. Notably, the broad-spectrum efficacy of RP151 was further validated against necrotrophic fungi (Botrytis cinerea) in tomato. RP151’s deployment could lead to a substantial reduction in the use of harmful pesticides, offering a sustainable, safe solution for enhancing plant defense against a variety of pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.